Hematology · ICMR

Beta thalassaemia

ICMR

Source:ICMR Guidelines for Thalassemia Management (2022)Thalassaemia International Federation Standards of Care (TIF 2021)MoHFW National Haemoglobinopathy Programme (2022)

Verified Apr 2026

Ask House about this guideline

Red Flags

Heart failure with iron overload (cardiac T2* <10 ms or LVEF <50%) — emergency cardiology + intensive chelation (combined deferiprone + deferoxamine)^[1]
Severe transfusion reaction (haemolytic, anaphylactic, TRALI, TACO) — stop transfusion, supportive care, reporting; investigate alloimmunisation^[1]
Pregnancy with thalassaemia — multidisciplinary preconception (cardiac and endocrine optimisation, switch deferoxamine, fetal medicine)^[1]
New endocrine deficit (hypothyroidism, diabetes, adrenal, gonadal) on chelation regimen — replacement therapy and chelation review^[1]

First-line treatment

Interventions

Regular transfusion programme (transfusion-dependent disease)^[1]
Pre-transfusion Hb target 9–10.5 g/dL (Hb 12 g/dL post-transfusion); leukoreduced, extended-antigen matched red cells; usual interval 2–4 weeks; phenotype matching from start to reduce alloimmunisation
Iron chelation when ferritin >1000 ng/mL or post-20 transfusions^[1]
Oral deferasirox first-line in most patients; subcutaneous deferoxamine for severe iron overload or pregnancy; combined deferasirox + deferiprone or deferoxamine + deferiprone for severe cardiac iron
Disease-modifying therapy^[1]
Hydroxyurea in selected non-transfusion-dependent thalassaemia raises HbF; luspatercept reduces transfusion need in adults with regular transfusion requirement
Curative — haematopoietic stem cell transplant or gene therapy^[1]
Matched sibling donor HSCT — best outcomes when transplanted before significant organ damage; matched unrelated/haploidentical donors with conditioning; gene therapy (betibeglogene autotemcel, exagamglogene autotemcel) for selected severe disease where access permits
Carrier screening and genetic counselling^[1]
All adults of reproductive age in high-prevalence regions; antenatal couple screening; prenatal diagnosis (chorionic villus sampling, amniocentesis) for at-risk couples; selective termination per local framework

First-line drug therapy

Drug	Class	Adult	Paediatric	Notes
Deferasirox^[1]	Oral iron chelator	20–40 mg/kg PO daily film-coated tablet; 14–28 mg/kg/day oral granules	Children ≥2 years 20–30 mg/kg/day	First-line in transfusion-dependent disease; monthly creatinine, LFT, urinalysis; rare hepatic, renal, gastrointestinal, ophthalmic, auditory adverse events
Deferoxamine (subcutaneous)^[1]	Parenteral iron chelator	30–50 mg/kg SC infusion over 8–12 h, 5–7 nights/week	20–40 mg/kg/day in children	Used in severe iron overload, pregnancy, deferasirox intolerance; growth delay in children; ophthalmic and auditory monitoring; injection-site reactions reduce adherence
Deferiprone^[1]	Oral iron chelator	75–100 mg/kg/day PO in 3 divided doses	Children ≥6 years per local label	Cardiac iron preferred (penetrates myocardium); weekly FBC for agranulocytosis; combined with deferasirox or deferoxamine for cardiac iron overload
Luspatercept^[1]	Erythroid maturation agent	1 mg/kg SC every 3 weeks; titrate to 1.25 mg/kg	—	Adults with transfusion-dependent thalassaemia requiring regular transfusion; reduces transfusion frequency; thrombosis risk; access varies
Hydroxyurea (selected non-transfusion-dependent)^[1]	Ribonucleotide reductase inhibitor / fetal Hb inducer	10–20 mg/kg/day PO; titrate by FBC	Same weight-based dosing	Selected non-transfusion-dependent thalassaemia and intermedia; raises HbF; teratogenicity; reversible cytopenia

Deferasirox^[1]

Oral iron chelator

Adult: 20–40 mg/kg PO daily film-coated tablet; 14–28 mg/kg/day oral granules
Paediatric: Children ≥2 years 20–30 mg/kg/day

First-line in transfusion-dependent disease; monthly creatinine, LFT, urinalysis; rare hepatic, renal, gastrointestinal, ophthalmic, auditory adverse events

Deferoxamine (subcutaneous)^[1]

Parenteral iron chelator

Adult: 30–50 mg/kg SC infusion over 8–12 h, 5–7 nights/week
Paediatric: 20–40 mg/kg/day in children

Used in severe iron overload, pregnancy, deferasirox intolerance; growth delay in children; ophthalmic and auditory monitoring; injection-site reactions reduce adherence

Deferiprone^[1]

Oral iron chelator

Adult: 75–100 mg/kg/day PO in 3 divided doses
Paediatric: Children ≥6 years per local label

Cardiac iron preferred (penetrates myocardium); weekly FBC for agranulocytosis; combined with deferasirox or deferoxamine for cardiac iron overload

Luspatercept^[1]

Erythroid maturation agent

Adult: 1 mg/kg SC every 3 weeks; titrate to 1.25 mg/kg
Paediatric: —

Adults with transfusion-dependent thalassaemia requiring regular transfusion; reduces transfusion frequency; thrombosis risk; access varies

Hydroxyurea (selected non-transfusion-dependent)^[1]

Ribonucleotide reductase inhibitor / fetal Hb inducer

Adult: 10–20 mg/kg/day PO; titrate by FBC
Paediatric: Same weight-based dosing

Selected non-transfusion-dependent thalassaemia and intermedia; raises HbF; teratogenicity; reversible cytopenia

Safety-net

Take iron chelator every day as prescribed and attend monitoring — undetected iron overload causes silent cardiac, hepatic, and endocrine damage^[1]
Plan pregnancy with your haematologist — switch deferasirox/deferiprone to deferoxamine ≥3 months pre-conception; cardiac and endocrine optimisation^[1]
Report new chest discomfort, breathlessness, palpitations, or weight gain — could signal cardiac iron overload requiring urgent intensification of chelation^[1]

Referral criteria

All confirmed thalassaemia major / intermediaHaematology service for transfusion programme, chelation, and surveillance^[1]
Severe cardiac iron overload (T2* <10 ms or HF)Cardiology and haematology with intensive chelation^[1]
Eligibility for HSCT or gene therapyTertiary haematology / BMT centre^[1]
Pregnancy with thalassaemia or carrier statusJoint haematology, obstetric, and antenatal genetics clinic^[1]

Clinical summary

Diagnosis, transfusion, iron chelation, and curative pathway for beta thalassaemia major and intermedia in adults and children.

References

1.ICMR Guidelines for Thalassemia Management (2022); Thalassaemia International Federation Standards of Care (TIF 2021); MoHFW National Haemoglobinopathy Programme (2022)

Drug

Class

Adult

Paediatric

Notes

Deferasirox^[1]

Oral iron chelator

20–40 mg/kg PO daily film-coated tablet; 14–28 mg/kg/day oral granules

Children ≥2 years 20–30 mg/kg/day

First-line in transfusion-dependent disease; monthly creatinine, LFT, urinalysis; rare hepatic, renal, gastrointestinal, ophthalmic, auditory adverse events

Deferoxamine (subcutaneous)^[1]

Parenteral iron chelator

30–50 mg/kg SC infusion over 8–12 h, 5–7 nights/week

20–40 mg/kg/day in children

Used in severe iron overload, pregnancy, deferasirox intolerance; growth delay in children; ophthalmic and auditory monitoring; injection-site reactions reduce adherence

Deferiprone^[1]

Oral iron chelator

75–100 mg/kg/day PO in 3 divided doses

Children ≥6 years per local label

Cardiac iron preferred (penetrates myocardium); weekly FBC for agranulocytosis; combined with deferasirox or deferoxamine for cardiac iron overload

Luspatercept^[1]

Erythroid maturation agent

1 mg/kg SC every 3 weeks; titrate to 1.25 mg/kg

—

Adults with transfusion-dependent thalassaemia requiring regular transfusion; reduces transfusion frequency; thrombosis risk; access varies

Hydroxyurea (selected non-transfusion-dependent)^[1]

Ribonucleotide reductase inhibitor / fetal Hb inducer

10–20 mg/kg/day PO; titrate by FBC

Same weight-based dosing

Selected non-transfusion-dependent thalassaemia and intermedia; raises HbF; teratogenicity; reversible cytopenia